We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.38B
AUM Growth
-$480M
Cap. Flow
+$130M
Cap. Flow %
2.42%
Top 10 Hldgs %
41.73%
Holding
224
New
23
Increased
133
Reduced
36
Closed
13

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$23.8M
2
GKOS icon
Glaukos
GKOS
+$20.8M
3
ARVN icon
Arvinas
ARVN
+$19.8M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
5
PACB icon
Pacific Biosciences
PACB
+$13.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$72.6M
2
GILD icon
Gilead Sciences
GILD
+$33.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$23.2M
4
TDOC icon
Teladoc Health
TDOC
+$19.5M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.28%
2 Industrials 0.53%
3 Technology 0.51%
4 Financials 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
A icon
126
Agilent Technologies
A
$36.8B
$2.28M 0.04%
29,800
-20,982
-41% -$1.51M
BIO icon
127
Bio-Rad Laboratories Class A
BIO
$8.08B
$2.25M 0.04%
+6,750
New +$2.2M
BNFT
128
DELISTED
Benefitfocus, Inc.
BNFT
$2.15M 0.04%
90,463
+2,300
+3% +$59K
CTLT
129
DELISTED
CATALENT, INC.
CTLT
$1.79M 0.03%
37,500
– –
MDCO
130
DELISTED
Medicines Co
MDCO
$1.45M 0.03%
28,900
-14,600
-34% -$582K
PFE icon
131
Pfizer
PFE
$141B
$1.44M 0.03%
42,160
– –
LABD icon
132
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$65M
$1.39M 0.03%
275
-285
-51% -$1.17M
ASND icon
133
Ascendis Pharma A/S
ASND
$16.5B
$1.31M 0.02%
13,600
-4,600
-25% -$513K
JNJ icon
134
Johnson & Johnson
JNJ
$599B
$1.29M 0.02%
+10,000
New +$1.32M
MRTX
135
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.24M 0.02%
15,900
-5,600
-26% -$526K
QURE icon
136
uniQure
QURE
$2.73B
$1.22M 0.02%
30,900
+3,300
+12% +$190K
GWPH
137
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.2M 0.02%
10,453
-1,900
-15% -$288K
RGNX icon
138
Regenxbio
RGNX
$557M
$1.2M 0.02%
33,700
+600
+2% +$24.3K
PTLA
139
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.17M 0.02%
+43,700
New +$1.23M
BPMC
140
DELISTED
Blueprint Medicines
BPMC
$1.16M 0.02%
15,800
+300
+2% +$25.9K
CRL icon
141
Charles River Laboratories
CRL
$10.6B
$1.1M 0.02%
+8,300
New +$1.11M
ARNA
142
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.08M 0.02%
23,517
-23,400
-50% -$1.32M
TEVA icon
143
Teva Pharmaceuticals
TEVA
$36.1B
$1.03M 0.02%
+150,000
New +$1.15M
XLRN
144
DELISTED
Acceleron Pharma
XLRN
$1.02M 0.02%
+25,800
New +$1.12M
ZLAB icon
145
Zai Lab
ZLAB
$2.32B
$971K 0.02%
30,000
-70,000
-70% -$2.4M
LH icon
146
Labcorp
LH
$23.1B
$936K 0.02%
6,487
-244
-4% -$35.6K
FATE icon
147
Fate Therapeutics
FATE
$325M
$933K 0.02%
60,100
+1,100
+2% +$21.1K
ZGNX
148
DELISTED
Zogenix, Inc.
ZGNX
$921K 0.02%
+23,000
New +$1.06M
MCK icon
149
McKesson
MCK
$97.3B
$810K 0.02%
5,924
-225
-4% -$31.9K
LVGO
150
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$754K 0.01%
+43,220
New +$1.31M
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2019 Portfolio in Review

As of Q3 2019, Bellevue Group held 224 positions worth $5.38B, down 8.2% from $5.86B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group's Q3 2019 filing shows 23 new, 133 increased, 36 reduced and 13 closed positions. Its largest new stake was Arvinas: 806,403 shares worth $17.4M. The largest sale was Celgene Corp, an estimated $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2019 buy was Arvinas: 806,403 shares worth $17.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2019, an estimated $23.8M increase.
  • Bellevue Group's biggest Q3 2019 reduction was Celgene Corp, cutting an estimated $72.6M.
  • Bellevue Group fully exited Avedro, Inc Common Stock in Q3 2019, selling an estimated $15.8M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.38B portfolio in Q3 2019.
  • Bellevue Group opened 23 new positions and closed 13 in Q3 2019.
  • Bellevue Group's portfolio value fell 8.2% quarter-over-quarter to $5.38B.

Based on Bellevue Group's 13F filing for Q3 2019, filed 14 Nov 2019.